Cytolytic Granules as Targets for Immunosuppressive Therapy: Selective Ablation of CTL by Leucyl-Leucine Methyl Ester

  • Dwain L. Thiele
  • Peter E. Lipsky


Cytotoxic lymphocytes constitute a subset of immune effector cells defined by their unique capacity for cell-mediated cytotoxicity. A number of observations have suggested that these cells play a crucial role in the mediation of allograft rejection, elimination of virally infected cells, and control of tumor cell growth. Pharamacologic agents capable of selectively modulating cytotoxic lymphocyte function are therefore likely to be of value not only in delineating the role of these effector cells in such immune responses but also in ameliorating a variety of disease states. Whereas a variety of currently available immunosuppressive agents are capable of impairing generation of activated cytotoxic T lymphocytes (CTL), such effects appear to relate largely to nonspecific impairment of cell proliferation or T-helper cell function necessary for CTL activation, and not to selective impairment of this lymphocyte effector function.


Graft Versus Host Disease Cytotoxic Lymphocyte Natural Killer Function Cytolytic Granule Dipeptide Ester 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Blazar BR, et al. (1990): Pretreatment of murine donor grafts with L-leucyl-L-leucine methyl ester: Elimination of graft-versus-host disease without detrimental effects on engraftment. Blood 75: 798–805Google Scholar
  2. Bleackley RC, et al. (1988): The isolation and characterization of a family of serine protease genes expressed in activated cytotoxic T lymphocytes. Immunol Rev 103: 5–19CrossRefGoogle Scholar
  3. Borrebaeck CAK (1988): Human mAbs produced by primary in vitro immunization. Immunol Today 9: 355CrossRefGoogle Scholar
  4. Golding H, Singer A (1985): Specificity, phenotype, and precursor frequency of primary cytolytic T lymphocytes specific for class II major histocompatibility antigens. J Immunol 135: 1610Google Scholar
  5. Goldman R, Kaplan A (1973): Rupture of rat liver lysosomes mediated by L-amino acid esters. Biochem Biophys Acta 318: 205CrossRefGoogle Scholar
  6. Jacobson S, et al. (1984): Measles virus-specific T4+ human cytotoxic T cell clones are restricted by class II HLA antigens. J Immunol 133: 754Google Scholar
  7. Korngold R, Sprent J (1985): Surface markers of T cells causing lethal graft-vs-host disease to class I vs class II H-2 differences. J Immunol 135: 3004Google Scholar
  8. Lanier LL, et al. (1986): Natural killer cells: Definition of a cell type rather than a function. J Immunol 137: 2735–2739Google Scholar
  9. McDonald JK, Barrett AJ (1986): Mammalian Proteases: A Glossary and Bibliography. London: Academic PressGoogle Scholar
  10. Odake S, et al. (1991): Human and murine cytotoxic T lymphocyte serine proteases: Subsite mapping with peptide thioester substrates and inhibition of enzyme activity and cytolysis by isocoumarins. Biochemistry 30: 2217–2227CrossRefGoogle Scholar
  11. Peters PJ, et al. (1991): Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med 173: 1099–1109CrossRefGoogle Scholar
  12. Poe M, et al. (1991): The enzymatic activity of human cytotoxic T-lymphocyte granzyme A and cytolysis mediated by cytotoxic T-lymphocytes are potently inhibited by a synthetic antiprotease, FUT-175. Arch Biochem Biophys 284: 215–218CrossRefGoogle Scholar
  13. Redelman D, Hudig D (1980): The mechanism of cell-mediated cytotoxicity. I. Killing by murine cytotoxic T lymphocytes requires cell surface thiols and activated proteases. J Immunol 124: 870–878Google Scholar
  14. Reeves JP, et al. (1981): Intracellular disruption of rat heart lysosomes by leucine methyl ester: Effects on protein degradation. Proc Nall Acad Sci USA 78: 4426CrossRefGoogle Scholar
  15. Thiele DL, Lipsky PE (1985a): Modulation of human natural killer cell function by L-leucine methyl ester: Monocyte-dependent depletion from human peripheral blood mononuclear cells. J Immunol 134: 786–793Google Scholar
  16. Thiele DL, Lipsky PE (1985b): Regulation of cellular function by products of lysosomal enzyme activity: Elimination of human natural killer cells by a dipeptide methyl ester generated from L-leucine methyl ester by monocytes or polymorphonuclear leukocytes. Proc Natl Acad Sci USA 82: 2468–2472CrossRefGoogle Scholar
  17. Thiele DL, Lipsky PE (1986): The immunosuppressive activity of L-leucyl-L-leucine methyl ester: Selective ablation of cytotoxic lymphocytes and monocytes. J Immunol 136: 1038–1048Google Scholar
  18. Thiele DL, Lipsky PE (1989): The impact of major histocompatibility complex (MHC) and non-MHC antigenic differences on graft-versus-host disease 348 D.L. THIELE AND P.E. LIPSKY mediated by helper T cells. Trans Assoc Am Physicians CII: 59–67Google Scholar
  19. Thiele DL, Lipsky PE (1990a): Mechanism of L-leucyl-Lleucine methyl ester-mediated killing of cytotoxic lymphocytes: Dependence on a lysosomal thiol protease, dipeptidyl peptidase I, that is enriched in these cells. Proc Natl Acad Sci USA 87: 83–87CrossRefGoogle Scholar
  20. Thiele DL, Lipsky PE (1990b): The action of leucylleucine methyl ester on cytotoxic lymphocytes requires uptake by a novel dipeptide-specific facilitated transport system and dipeptidyl peptidase I-mediated conversion to membranolytic products. J Exp Med 172: 183–194CrossRefGoogle Scholar
  21. Thiele DL, Lipsky PE (1991): Apoptosis is an essential step in leucyl-leucine methyl ester (Leu-Leu-OMe) mediated killing of cytotoxic lymphocytes and myeloid cells. FASEB J 5: A937Google Scholar
  22. Thiele DL, et al. (1983): Phenotype of the accessory cell necessary for mitogen-stimulated T and B cell responses in human peripheral blood: Delineation by its sensitivity to the lysosomotropic agent, L-leucine methyl ester. J Immunol 131: 2282Google Scholar
  23. Thiele DL, et al. (1987a): Lethal graft-vs-host disease across major histocompatibility barriers: Requirements for leucyl-leucine methyl ester sensitive cytotoxic T cells. J Immunol 138: 51–57Google Scholar
  24. Thiele DL, et al. (1987b): Leucyl-leucine methyl ester treatment of donor cells permits establishment of immunocompetent parent —.F1 chimeras that are selectively tolerant of host alloantigens. J Immunol 139: 2137–2142Google Scholar
  25. Thiele DL, et al. (1988): Lethal graft-vs-host disease induced by a class II MHC antigen only disparity is not mediated by cytotoxic T cells. J Immunol 141: 3377–3382Google Scholar
  26. Thiele DL, et al. (1989): Intestinal graft-vs-host disease is initiated by donor T cells distinct from classic cytotoxic T lymphocytes. J Clin Invest 84: 1947–1956CrossRefGoogle Scholar
  27. Thompson PA, et al. (1984): Regulation of human B cell proliferation by prostaglandin E,. J Immunol 133: 2446–2453Google Scholar
  28. Tschopp J, Nabholz M (1990): Perforin-mediated target cell lysis by cytolytic T lymphocytes. Annu Rev Immunol 8: 279–302CrossRefGoogle Scholar

Copyright information

© Birkhäuser Boston 1993

Authors and Affiliations

  • Dwain L. Thiele
  • Peter E. Lipsky

There are no affiliations available

Personalised recommendations